Kornimate/medical-research-clean huggingface dataset:
diagnostic efficacy of cnn in predicting intraoperative complications and postoperative outcomes in smile

Conditions: Deep Convolutional Neural Network; Small-incision Lenticule Extraction (SMILE) Surgery; Intraoperative Complications; Postoperative Outcomes

Summary: to evaluate the diagnostic efficiency of the neural network in predicting complications of small incision lenticule extraction in a multi-center cross-sectional study.

the primary cause of global visual impairment currently is refractive error, and small incision lenticule extraction (smile) using femtosecond laser for corneal stromal lenticule extraction can alter the refractive power. however, complications such as opaque bubble layer (obl), negative pressure detachment, and black spots may arise during the smile laser scanning process due to individual differences in corneal characteristics, significantly affecting the normal course of surgery and postoperative recovery. experienced docters can often predict intraoperative complications based on scan images, patient cooperation, and other factors, but the learning curve is relatively long. at present, artificial intelligence has achieved the accuracy comparable to human physicians in the interpretation of medical imaging of many different diseases.previously, we have trained a deep convolutional neural network for predicting intraoperative complications in smile procedures. the current multi-center study is designed to evaluate the efficacy of the convolutional neural network based algorithm in predicting intraoperative complications and to assess its utility in the real world.

Eligibility criteria:
inclusion criteria: * a condition in which the spherical equivalent refractive error of an eye is ≤-0.50 d when ocular accommodation is relaxed; * age ≥18 years; * spherical equivalent (se) ≥-10.0d; * corrected distance visual acuity (cdva) ≥16/20; * stable myopia for at least 2 years; * no contact lenses wearing for at least 2 weeks. exclusion criteria: * the presence or history of eye conditions other than myopia and astigmatism, such as keratoconus or external eye injury; * a history of eye surgery; * the presence or history of systemic diseases.

Keywords: femtosecond laser small-incision lenticule extraction intraoperative complications deep convolutional neural network postoperative outcomes
study of sensorimotor compatibility effects in bipolar affective disorder.

Conditions: Bipolar Affective Disorder

Summary: based in an embodied approach of cognition, several studies have highlighted a direct link between perception of an object or an emotion and the associated motor responses. this study investigated in patients suffering from bipolar affective disorders whether the perception of emotional words involves an automatic sensorimotor simulation of approach and avoidance behaviors, and whether the perception of an object involves an automatic sensorimotor simulation of object prehension (affordance). we hypothesize that, in this pathology, low level (sensorimotor) cognitive processes are preserved whereas high-level (attentional) are altered. 20 patients suffering from bipolar affective disorders and 20 healthy controls will be recruited. the main objective is the emergence of sensorimotor compatibility effects in approach-avoidance task with emotional stimuli (gain between compatible vs incompatible conditions).


Eligibility criteria:
inclusion criteria: for patients: * affiliated or entitled to a social security * aged between 18 and 55 * patients of both sexes suffering from bipolar disorders (dsm v criteria) whatever the subtype * stabilized from a point of view clinical and therapeutic * euthymic (score \<7 at the hamilton scale, and score \<8 at young's scale) * must have given their informed consent before their participation in the study * be right-handed (score\> 14 on the laterality scale) for control group: * affiliated or entitled to a social security * must have given their informed consent before their participation in the study * be right-handed (score\> 14 on the lateral scale) * aged 18 to 55 matched by age (± 5 years), sex, and on the study level of patients (years of schooling after primary school ± 2 years) exclusion criteria: for patients: * thymic acute decompensation * hamilton scale \> 8, young's scale \> 9 * montreal cognitive assessment (moca) \<26 * history neurological pathology with cerebral impairment or serious somatic disease * disorders related to the use of a psychoactive substance, as defined by the dsm-v (abuse, dependence or withdrawal) within 6 months. * iq \< 70 * history of head trauma for control group: * history of head trauma * neurological pathology with cerebral impairment or serious somatic disease * psychotropic treatment * disorders related to the use of a psychoactive substance, as defined by the dsm-v (abuse, dependence or withdrawal) * iq \< 70

Keywords: bipolar affective disorders cognition emotion embodiment sensorimotor simulation
differential study of muscle transcriptome

Conditions: ALS; SMA; SBMA

Summary: to isolate biomarkers of als in muscle

at present, there is no validated biological diagnostic marker for amyotrophic lateral sclerosis (als). the main objective of the study is to isolate a set of genes that are specifically dysregulated in muscle from als patients. gene profiling in muscle will be compared between als patients and patients with other motor neuron diseases (sma and sbma)

Eligibility criteria:
inclusion criteria : - patient with als, sma, or sbma exclusion criteria : * indication against biopsy (allergy to anesthetics local haemostasis disorders) * treatments that can affect muscle metabolism

Keywords: als motor neuron diseases transcriptome
efficacy of a couple-focused mhealth symptom self-management program

Conditions: Prostate Cancer

Summary: in this study, the investigators propose to test the efficacy of a couple-focused, web-based tailored prostate cancer symptom management program, prostate cancer education and resources for couples (perc) in a randomized clinical trial. a two-group (perc versus national cancer institute (nci) website plus treatment as usual) randomized controlled design will be used, and data will be collected at baseline (t1), 4 (t2), 8 (t3), and 12 months (t4) among 300 patients completing initial treatment for localized prostate cancer and their intimate partners (i.e., 600 participants in total).

this randomized clinical trial aims to test the efficacy of a couple-focused, web-based tailored prostate cancer symptom management program, prostate cancer education and resources for couples (perc). the study participants will include 300 patients completing initial treatment for localized prostate cancer and their intimate partners (i.e., 300 dyads and 600 individuals). after informed consent, we will conduct baseline assessment (t1), randomly assign eligible participants to either perc or the national cancer institute (nci) website, and then collect data at 4 (t2), 8 (t3), and 12 months (t4) post-t1.

Eligibility criteria:
inclusion criteria: the eligible patients must 1. be 40 to 75 years of age 2. be within 16 weeks (4 months) after completing initial treatment for localized prostate cancer as confirmed by patient and biopsy pathology report) with curative intent, i.e., surgery or radiotherapy +/- hormonal treatment; 3. have no previous cancer history within the past 2 years and not currently in treatment for cancer, or have a concurrent cancer (excluding non-melanomatous skin cancer); 4. experience prostate cancer-specific and/or general symptoms; 5. have a partner who is willing to participate. the eligible partners must 1. be 18 years or older 2. be identified as the partner by the patient 3. not have been diagnosed with cancer or receiving treatment for cancer within the past 12 months (non-melanomatous skin cancer diagnosis/treatment is acceptable) so that couples can focus their efforts on managing prostate cancer. exclusion criteria: patients and their partners will be excluded from the study if they: * do not read and speak english (evidenced by their understanding and responses to screening questions and self-reported ability to read english); * have cognitive impairment (assessed by the short portable mental status questionnaire).

Keywords: symptom family research self-management caregiving social support mhealth healthy behavior self-efficacy quality of life care transition
fluid responsiveness predicted by ptco2 in critically ill patients

Conditions: Circulatory Failure

Summary: our goal was to study the feasibility of predicting fluid responsiveness by transcutaneous partial pressure of oxygen (ptco2) in the critically ill patients.

the clinical determination of the intravascular volume can be extremely difficult in critically ill patients. although hemodynamic maximization was proposed, this approach was associated with a risk of fluid overload and excessive inotropic support. therefore, fluid optimization was seen as a significant step forward and has been shown to decrease complications. significant effort has been devoted to defining and developing simple means for predicting fluid responsiveness, i.e. whether the patient will benefit from fluid administration. passive leg raising (plr), a bedside performed test, could be used to accurately predict fluid responsiveness in most conditions. however, most parameters that provide information about fluid responsiveness during volume expansion and plr are invasive and time-consuming. a completely noninvasive and atraumatic parameter to predict fluid responsiveness might be need urgently. transcutaneous partial pressure of oxygen (ptco2), a measure to detect tissue ischemia or inadequate perfusion, might reflect the change in cardiac output, thus predict fluid responsiveness. the purpose of this study was to study the feasibility of predicting fluid responsiveness by transcutaneous partial pressure of oxygen in the critically ill patients.

Eligibility criteria:
inclusion criteria: * clinical signs of inadequate tissue perfusion defined as systolic blood pressure \ 40 mmhg in previously hypertensive patients or the need for vasopressive drugs (dopamine \> 5 ug/kg/min or norepinephrine); urine output \< 0.5 ml/kg/hr for 2 hrs; tachycardia; presence of skin mottling. exclusion criteria: * pregnancy, age of less than 18 years, contraindication to passive leg raising test, cardiac arrhythmias, cardiogenic pulmonary edema, the presence of abdominal compartment syndrome and refusal to participate in the study

Keywords: fluid responsiveness; passive leg raising
water uptake for health in amhara pilot

Conditions: Trachoma

Summary: trachoma is a blinding disease caused by ocular strains of chlamydia trachomatis. the carter center and proctor foundation have been jointly conducting trachoma research in the goncha siso enese woreda of amhara for the past 8 years, through a series of clinical trials. we have found that repeated mass administration of oral azithromycin can greatly reduce the prevalence of trachoma, but mass antibiotics have been unable thus far to eliminate infection. the world health organization recommends not only antibiotics for control of trachoma, but an entire safe strategy (surgery for in-turned eyelids, antibiotics, facial hygiene promotion, and environmental improvements such as latrines and water points). trachoma is more common in villages and households with poor access to water and latrines, so improving the public health infrastructure is thought to be important for limiting transmission of trachoma. however, there is very little evidence to support the efficacy of installing new water points for trachoma. there has been only one previous attempt to study the role of hand dug well installation for trachoma control, and this study, conducted in niger, found that installing wells was not effective. we now propose a project to improve the public health infrastructure of goncha siso enese woreda by helping with the construction of water points (e.g., hand-dug wells) and providing hygiene education, in order to determine whether improving access to water and hygiene information will be effective for control of trachoma and soil-transmitted helminths.


Eligibility criteria:
inclusion criteria: * all residents residing in the state-teams which are randomly selected for this study. exclusion criteria: * refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Keywords: trachoma soil transmitted helminths water hand washing
a study to demonstrate the bioequivalence of sitagliptin/metformin combination tablets and concomitant administration of sitagliptin and metformin as individual tablets (0431a-048)

Conditions: Type 2 Diabetes

Summary: a two-part study to demonstrate the bioequivalence of a single dose of the final market image (fmi) of sitagliptin /metformin (50/500 and 50/1000 mg) fixed-dose combination (fdc) tablet and co-administration of a single dose of sitagliptin (50 mg) and metformin ( 500 or 1000 mg) as individual tablets. subject will only participate in one part, receiving treatment a and b (part i) or treatment c and d (part ii).


Eligibility criteria:
inclusion criteria: * female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception * subject is in good health and is a non-smoker * subject is willing to avoid strenuous physical activity during the study * subject agrees to refrain from eating grapefruit or grapefruit products during the study exclusion criteria: * subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder. subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * subject consumes excessive amounts of alcohol or caffeinated beverages * subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks * subject has a history of significant multiple and/or severe allergies to prescription or non-prescription drugs or food * subject has a history of hypersensitivity to metformin, sitagliptin, or sitagliptin/metformin * subject is a regular user or past abuser of any illicit drugs * subject is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies during the study. * subject is a nursing mother
direct peroral cholangioscopy by using an ultra-slim upper endoscope

Conditions: Bile Duct Stricture; Choledocholithiasis

Summary: this study was aimed to to evaluate the efficacy of the new multibending ultra-slim endoscope compared with a conventional ultra-slim endoscope for free-hand insertion of an endoscope into the bile duct for direct poc.

currently available peroral cholangioscopy (poc) is a duodenoscopy-assisted procedure that does not involve directly inserting an endoscope into the biliary tree. a prototype multibending (mb) ultra-slim endoscope has been developed as a dedicated cholangioscope to overcome the technical difficulties of direct poc. in this study, the investigators evaluated the efficacy of the new mb ultra-slim endoscope compared with a conventional ultra-slim endoscope for free-hand insertion of an endoscope into the bile duct for direct poc without the assistance of accessories. the primary outcome was the technical success of free-hand insertion of the endoscope during direct poc, which was defined as successful insertion of the endoscope through the ampulla of vater and advancement of the endoscope up to the bifurcation or to the obstructed segment of the biliary tree without any accessories within 15 min.

Eligibility criteria:
inclusion criteria: * biliary disease requiring diagnostic and/or therapeutic direct poc * distal common bile duct (cbd) dilation \> 8 mm * previous sphincteroplasty, including major endoscopic sphincterotomy and/or endoscopic papillary balloon dilatation during a prior ercp * ability to provide informed consent exclusion criteria: * presence of any contraindication to ercp * bleeding tendency (international normalized ratio \> 1.5 or platelet count \< 50,000/ mm3) * diffuse stricture of the distal cbd * diagnosis of pancreatic cancer or tumor at the ampulla of vater (aov) * altered gastrointestinal anatomy or significant duodenal obstruction

Keywords: cholangioscopy
differential effects of rhgh vs. rhigf-1 on cardiovascular risk factors

Conditions: Growth Hormone Deficiency

Summary: the purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (igf-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.

insulin-like growth factor-1 (igf-1) in some circumstances acts as the mediator of the metabolic effects of growth hormone. however, there is some evidence to suggest that growth hormone (gh) and igf-1 act differently in some metabolic pathways. we will study the differences between gh and igf-1 when provided as therapy for growth hormone deficiency in adults. specifically we will be assessing if either medication impacts cardiovascular risk factors and if so do they impact risk factors differently. ten adult males ages 18-65 who are growth hormone deficient on stable medications and with stable magnetic resonance imaging (mri) findings (in the event of a known pituitary mass) will be recruited for the study.

Eligibility criteria:
inclusion criteria: * adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable mris x 2 years in the setting of a known pituitary mass. exclusion criteria: * female gender * current gh use or gh use within three months of the study * diabetes * hypoglycemia * liver or kidney disease * use of drugs that could increase gh secretion (i.e. l-dopa) * alcohol or substance abuse * use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months.

Keywords: rhgh rhigf-1
thoracic fluid content and acute lung injury

Conditions: Acute Lung Injury

Summary: to study the association of the thoracic fluid content and acute lung injury during liver transplantation.

acute lung injury is not uncommon after liver transplantation. a new monitor non-invasive cardiac output monitor (nicom) is designed to measure thoracic fluid content. the investigators attempt to use the parameter thoracic fluid content to investigate its relationship with acute lung injury in liver transplant recipients.

Eligibility criteria:
inclusion criteria: * end stage liver disease scheduled for liver transplantation in national taiwna university hospital. exclusion criteria: * allergic reaction * history of aortic regurgitation * pre-existing pulmonary disease
a study to assess real-world use, safety, and effectiveness of oral upadacitinib in adult and adolescent (>=12 years old) participants with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis (ad; also known as atopic eczema) is an inflammatory skin disease. the safety and effectiveness of upadacitinib for ad has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult ad participants \>=12 years old in the real-world setting. upadacitinib is an approved drug being developed for the treatment of ad. around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of ad in routine clinical practice will be enrolled worldwide. participants will receive oral upadacitinib as prescribed by their physician. data from these participants will be collected for approximately 2 years. there will be no additional burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.


Eligibility criteria:
inclusion criteria: * physician confirmed diagnosis of atopic dermatitis (ad) or atopic eczema at baseline. * symptom onset \>=1-year prior to baseline. * initiation of upadacitinib treatment for ad is indicated and prescribed per local label. * the decision to prescribe upa is made prior to and independently of study participation. * medical and medication history available for previous 6 months. * participants who can understand the questionnaires, with parental support as required for adolescents. * participants who are able to understand and communicate with the investigator and comply with the requirements of the study. * participants who are willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., tablet). * participants who are willing and able to complete the patient-reported questionnaires. exclusion criteria: - participants who are currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation).

Keywords: atopic dermatitis atopic eczema upadacitinib rinvoq
investigation of the spatio-temporal gait parameters in individuals with hemiparesis: effect of lateralization

Conditions: Hemiparesis

Summary: the aim of this study was to investigate the effect of lateralization on the spatio-temporal characteristics of gait in individuals with hemiparesis.

a total of 108 individuals within the age range of 20-65 and 36 of whom are right hemiparetic (group1; 16f, 20m), 36 of whom are left hemiparetic (group2; 16f, 20m) and 36 of whom are healthy (group3; 19f, 17m) have been included in the study. bts g-walk gait analysis system has been used to assess the spatio-temporal gait characteristics.

Eligibility criteria:
inclusion criteria: for the hemiparetic individuals * being between the ages of 20-65, * having a stroke for the first time and one-sidedly, * having a stable clinical state, * having no cognitive disorder (hodkinson mental test ≥ 8), * having ≤ 3 from modified rankin score, * having no problems with vision and hearing. for the healthy control group; * being between the ages of 20-65 * having no neurological, musculosceletal, cardiac and cognitive problems that was undergone before and may affect walking. exclusion criteria: * the existence of vision and hearing problems in both study and control groups, * the existence of orthopedic, neurological and psychiatric problems that may affect walking.

Keywords: hemiparesis lateralization spatio-temporal analysis gait